AIA
AZN icon

Avalon Investment & Advisory’s AstraZeneca AZN Stock Holding History

Avalon Investment & Advisory’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$410K Sell
2,957
-240
-8% -$32.3K 0.01% 267
2022
Q4 		$433K Sell
3,197
-555
-15% -$69.6K 0.01% 261
2022
Q3 		$412K Sell
3,752
-227
-6% -$28.8K 0.01% 245
2022
Q2 		$526K Sell
3,979
-282
-7% -$37K 0.01% 230
2022
Q1 		$565K Sell
4,261
-3,922
-48% -$470K 0.01% 239
2021
Q4 		$953K Sell
8,183
-7,140
-47% -$840K 0.02% 211
2021
Q3 		$1.84M Sell
15,323
-15,225
-50% -$1.77M 0.04% 197
2021
Q2 		$3.66M Sell
30,548
-1,938
-6% -$213K 0.08% 161
2021
Q1 		$3.23M Sell
32,486
-12,038
-27% -$1.21M 0.07% 161
2020
Q4 		$4.45M Sell
44,524
-537
-1% -$56.9K 0.09% 140
2020
Q3 		$4.94M Sell
45,061
-1,010
-2% -$112K 0.11% 129
2020
Q2 		$4.87M Sell
46,071
-10,831
-19% -$1.12M 0.11% 129
2020
Q1 		$5.08M Buy
56,902
+23,669
+71% +$2.23M 0.13% 136
2019
Q4 		$3.31M Sell
33,233
-3,856
-10% -$363K 0.07% 182
2019
Q3 		$3.31M Sell
37,089
-1,277
-3% -$111K 0.07% 176
2019
Q2 		$3.17M Buy
38,366
+3,837
+11% +$301K 0.07% 179
2019
Q1 		$2.79M Sell
34,529
-775
-2% -$61.1K 0.06% 194
2018
Q4 		$2.68M Sell
35,304
-6,377
-15% -$498K 0.07% 188
2018
Q3 		$3.3M Buy
41,681
+13,138
+46% +$994K 0.09% 196
2018
Q2 		$2M Sell
28,543
-813
-3% -$58.5K 0.06% 224
2018
Q1 		$2.05M Buy
29,356
+3,825
+15% +$265K 0.06% 211
2017
Q4 		$1.77M Buy
25,531
+2,797
+12% +$189K 0.06% 211
2017
Q3 		$1.54M Buy
22,734
+4,430
+24% +$280K 0.05% 204
2017
Q2 		$1.25M Buy
18,304
+3,308
+22% +$216K 0.04% 229
2017
Q1 		$934K Buy
+14,996
New +$873K 0.03% 252
2016
Q1 		– Sell
-7,098
Closed -$482K – 262
2015
Q4 		$482K Sell
7,098
-4,667
-40% -$306K 0.02% 207
2015
Q3 		$749K Buy
11,765
+7,152
+155% +$471K 0.03% 171
2015
Q2 		$294K Buy
+4,613
New +$316K 0.01% 236

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Avalon Investment & Advisory's AZN Position: Q1 2023 in Review

Avalon Investment & Advisory reduced its AstraZeneca (AZN) stake by 7.5% in Q1 2023, selling an estimated $32.3K and leaving 2,957 shares worth $410K. The position accounts for 0.01% of the portfolio, ranked #267.

Avalon Investment & Advisory first reported a position in AZN in Q2 2015 and has held it in 28 quarters since. The position peaked at $5.08M in Q1 2020. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

  • Avalon Investment & Advisory held 2,957 shares of AstraZeneca worth $410K as of Q1 2023.
  • Avalon Investment & Advisory sold 240 AstraZeneca shares in Q1 2023, an estimated $32.3K.
  • AstraZeneca made up 0.01% of Avalon Investment & Advisory's portfolio in Q1 2023, its #267 holding.
  • Avalon Investment & Advisory first reported a position in AstraZeneca in Q2 2015 and has held it in 28 quarters since.
  • Avalon Investment & Advisory's AstraZeneca position peaked at $5.08M in Q1 2020.
  • 1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Avalon Investment & Advisory's 13F filing for Q1 2023, filed 15 May 2023.